治疗反应监测
本综述讨论感染性疾病治疗反应监测的现状,指出目前缺乏客观评价抗菌治疗效果的临床标准或推荐影像方法,疗效主要依据患者主观临床反应判断;分子影像可无创定量检测体内生物学过程,18F-FDG-PET/CT在评估感染性疾病治疗反应方面较传统影像更有前景;文章重点介绍结核分枝杆菌、椎间盘炎、感染性人工血管移植物、侵袭性真菌感染和寄生虫病的分子影像监测研究,并讨论HIV相关脂肪营养不良的功能成像监测及优化无创反应评估的挑战与新数据。
要点
- 目前尚无临床标准或推荐影像方法客观评价抗菌治疗效果,疗效依据患者主观临床反应判断。
- 18F-FDG-PET/CT评估感染性疾病治疗反应较传统影像更有前景。
- 分子影像可无创、定量检测体内生物学过程,用于监测结核分枝杆菌等感染的治疗反应。
核心结论
- 感染性疾病治疗反应监测中,可靠的非侵入性反应评估生物标志物仍存在争议。
- 目前尚无临床标准或推荐影像方法客观评价抗菌治疗效果,疗效依据患者主观临床反应判断。
- 分子影像能无创、定量检测体内生物学过程;18F-FDG-PET/CT评估感染性疾病治疗反应较传统影像更有前景。
研究设计与样本
- 综述,聚焦结核分枝杆菌,并涵盖椎间盘炎、感染性人工血管移植物、侵袭性真菌感染和寄生虫病等感染。
主要发现
- 分子影像可无创、定量检测体内生物学过程,较传统影像更适合评估感染性疾病治疗反应。
- 18F-FDG-PET/CT评估感染性疾病治疗反应较传统影像更有前景。
- 目前疗效依据患者主观临床反应判断,尚无客观评价抗菌治疗效果的临床标准或推荐影像方法。
关键数值与推荐
- 目前尚无临床标准或推荐影像方法客观评价抗菌治疗效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Monitoring response to treatment is a key element in the management of infectious diseases, yet controversies still persist on reliable biomarkers for noninvasive response evaluation. Considering the limitations of invasiveness of most diagnostic procedures and the issue of expression heterogeneity of pathology, molecular imaging is better able to assay in vivo biologic processes noninvasively and quantitatively. The usefulness of 18F-FDG-PET/CT in assessing treatment response in infectious diseases is more promising than for conventional imaging. However, there are currently no clinical criteria or recommended imaging modalities to objectively evaluate the effectiveness of antimicrobial treatment. Therapeutic effectiveness is currently gauged by the patient's subjective clinical response. In this review, we present the current studies for monitoring treatment response, with a focus on Mycobacterium tuberculosis, as it remains a major worldwide cause of morbidity and mortality. The role of molecular imaging in monitoring other infections including spondylodiscitis, infected prosthetic vascular grafts, invasive fungal infections, and a parasitic disease is highlighted. The role of functional imaging in monitoring lipodystrophy associated with highly active antiretroviral therapy for human immunodeficiency virus is considered. We also discuss the key challenges and emerging data in optimizing noninvasive response evaluation.
引用
- Sathekge MM, Ankrah AO, Lawal I, et al. Monitoring Response to Therapy. Semin Nucl Med. 2017. PMID: 29452619. doi:10.1053/j.semnuclmed.2017.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。